Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Anderson, SC
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Anderson, SC
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Greer, SC
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Greer, SC
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Goodlettsville, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Knoxville, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Murfreesboro, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Arlington, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
San Antonio, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Spokane, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Walla Walla, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Wenatchee, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
California City, CA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
California City, CA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fort Myers, FL
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Saint Joseph, MO
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Norfolk, VA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fort Smith, AR
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rogers, AR
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rogers, AR
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Irvine, CA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Irvine, CA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Atlanta, GA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Baton Rouge, LA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Metairie, LA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
New Orleans, LA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Quincy, MA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Quincy, MA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jackson, MS
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fairborn, OH
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fairborn, OH
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Exton, PA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Exton, PA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
Pittsburgh, PA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Pflugerville, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Pflugerville, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Murray, UT
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Murray, UT
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Everett, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Everett, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Seattle, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Madison, WI
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
St. John's,
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
St. John's,
Click here to add this to my saved trials
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DS Biopharma Site
mi
from
Philadelphia, PA
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DS Biopharma Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DS Biopharma Site
mi
from
Cape Town,
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DS Biopharma Site
mi
from
Cape Town,
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 702
mi
from
Houston, TX
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 702
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0011 733
mi
from
Wilmington, NC
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0011 733
mi
from
Wilmington, NC
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 733
mi
from
Dallas, TX
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 733
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0011 209
mi
from
Edmonton,
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0011 209
mi
from
Edmonton,
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 704
mi
from
West des Moines, IA
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 704
mi
from
West des Moines, IA
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0011 708
mi
from
Los Angeles, CA
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0011 708
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 706
mi
from
Washington,
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 706
mi
from
Washington,
Click here to add this to my saved trials